All Categories
ENEN
DNA Therapeutic

DNA Therapeutic

Home >  Modality  >  Animal Biologics  >  DNA Therapeutic

Modality

DNA Therapeutics

DNA Therapeutics for Human Use

The primary development focus of naked plasmid therapeutics is angiogenic factors gene therapy. As of now, there are a total of two approved naked plasmid drugs for human use globally: Neovasculgen, launched in Russia in 2011, and Collategene, introduced to the Japanese market in 2019. Several other naked plasmid drugs are currently in the Phase II-III clinical stages. Encoding genes include HGF, VEGF-A, SDF-1 (CXCL12), and among others.

DNA Therapeutics for Animal Use

Different from human medicines, DNA vaccines have been more successful for animal use, including veterinary and pet.

Table 1. Approved naked plasmid DNA in human and animal

Application Product Species Target Indication Company Licensed Date/ Country
Gene therapy Neovasculgen, Cambiogenplasmid, PI-VEGF165 Human VEGF-A CLI, critical limb ischemia Human Stem Cell Institute 2011/ Russia
Gene therapy Collategene, beperminogene perplasmid, AMG0001 Human HGF CLI, critical limb ischemia AnGes 2019/Japan
Gene therapy LifeTideSW5 Swine Porcine growth hormone-releasing hormone (GHRH) Increase the number of piglets weaned VGX Animal Health 2008/Australia
Cancer Immunotherapy Oncept Canine Human tyrosinase Oral malignant melanoma (OMM) Merial, Boehringer Ingelheim Animal Health 2010/USA
Antimicrobials Zelnate Bovine CpG motif Bovine respiratory disease (BRD) due to Mannheimia haemolytica Bayer Animal Health, Elanco 2015/USA
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Plasmid DNA
Reference:

[1] Pagliari S, Dema B, Sanchez-Martinez A, Montalvo Zurbia-Flores G, Rollier CS. DNA Vaccines: History, Molecular Mechanisms and Future Perspectives. J Mol Biol. 2023 Dec 1;435(23):168297. doi: 10.1016/j.jmb.2023.168297.

Get a Free Quote

Get in touch